久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

美國(guó)Structural Bioinformatics, Inc. (SBI) 
Structural Bioinformatics 公司是計(jì)算蛋白質(zhì)組領(lǐng)域的全球領(lǐng)導(dǎo)者，希望將其蛋白質(zhì)建模系統(tǒng)從基于Oracle和 Sun的基礎(chǔ)設(shè)施移植到一種新的解決方案上，最終決定用于IBM eServer xSeries服務(wù)器的Linux和Linux集群的 DB2，以及在Web上傳送事務(wù)的IBM WebSphere Application Server的解決方案。對(duì)于一系列計(jì)算，其Linux操作系統(tǒng)與IBM硬件和DB2的完美結(jié)合可以幫助他們將基準(zhǔn)成本從每次計(jì)算28美元左右降低到1美元以下。

Structural Bioinformatics, Inc. (SBI) is a world leader in proteomics-driven drug discovery – the large-scale generation and use of protein structural information to accelerate the discovery and optimization processes.

SBI’s Genes to Leads technology, employing SBI’s proprietary DynaPharm and CombiLib technologies, offers a truly practical response to the wealth of new drug targets emerging from genomic sequencing efforts around the world for the human genome and the genomes of hundreds of infectious disease agents. Our technology reliably produces drug leads – in 60-120 days - starting with the sequence alone, with an efficiency that is more than 1,000-fold greater than state-of-the-art high throughput screening (HTS). The efficiencies in speed and cost are the direct result of the use of our underlying proprietary computational proteomics platform that allows us to generate X-ray quality protein structures at a fraction of the cost and time.